What this study is
Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of patients with metastatic breast cancer (MBC). The goal of this research is to understand symptom burden and quality of life trajectories in this population and how treatments guide care management decisions.
What's being tested
- Health-Related Quality of Life (QOL) questionnaires
Intervention · OTHER
Participants can complete questionnaires online, via tablet in clinic, or via paper and pencil in clinic
- Medical Chart Review
Intervention · OTHER
Data will be collected from the participants electronic medical record
Study details
- Official title
- Prospective Evaluation of Quality of Life in Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease
- Sponsor
- University of California, San Francisco
- Conditions
- Breast Cancer, Quality of Life · Breast Cancer, Metastatic · Breast Cancer, Metastatic Breast Cancer · Leptomeningeal Metastasis of Breast Cancer · Brain Metastases From Breast Cancer
- Enrolling
- 200 people
- Starts
- 2026-06-15
- Est. completion
- 2035-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Be male or female 18 years of age or older.
- Have stage 4 (metastatic) breast cancer with spread to the brain parenchyma and/or leptomeninges.
- Have the intention to start or continue anticancer therapy.
- Be able to provide informed consent.
- Be able to speak and read English.
You can't join if
- Participants who are not on any anticancer therapy and are not planning to start any anticancer therapy will be excluded from the study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of California, San Francisco
San Francisco, California, United States
- Amy Langdon · Contact877-827-3222Amy.DeLuca@ucsf.edu
- Contactcancertrials@ucsf.edu
- Laura Huppert, MD · Principal investigator
- Michelle Melisko, MD · Principal investigator
Study team
Sponsor
University of California, San Francisco
Study ID 26757
Principal investigator
Laura Huppert, MD
University of California, San Francisco
Principal investigator
Michelle Melisko, MD
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.